Key Drivers
- Robust Liquidity
- High Leverage
- Strong Margins
AIAI Summary
ALNY is now a commercial-execution investment, with upside contingent on AMVUTTRA sustaining durable TTR penetration beyond the early patient-inflow surge; investors should wait for evidence of stable patient starts, pricing, and guidance before treating the sell-off as a buying opportunity, given concentrated franchise and debt sensitivity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Robust Liquidity
- •High Leverage
- •Strong Margins
ALNY delivers strong growth, margins, cash generation and liquidity, but high debt, interest burden and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Recent pullback
- •Key support
- •Overhead resistance
ALNY is mixed over the last month, with weakening near-term momentum below short averages; stay cautious unless it reclaims $250, while a break below $236–$237 would be bearish.
Declined after peaking near $267 on 2026-09-02
Sentiment & News
Key News Insights:
- •Legal investigation risk
- •Bullish analyst consensus
- •Clinical progress
Alnylam faces a legal-investigation overhang after a sharp sell-off, but bullish analyst targets, institutional buying, and advancing clinical programs support a constructive long-term outlook.
Near-term volatility may persist from litigation concerns, while positive fundamentals could support longer-term valuation recovery
Similar Companies in Healthcare
Other companies in the same sector with AI ratings